Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes
doi: 10.1016/j.nmni.2020.100756 118 WeberAGChauASEgebladMBarnesBJJanowitzT
Acetyl-l-Carnitine in the Treatment of Peripheral Neuropathies: A Narrative Review
We dig into: Lilly's decision to stop disclosing its Phase 1 pipeline The Camurus fluid crystal technology deal and what it means for long-acting GLP-1s Eloralintide Lilly's selective amylin agonist and potential dark horse in obesity medicine How eloralintide compares to Novo Nordisk's cagrilintide Why the future of obesity treatment is a toolbox, not a scoreboard The access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gaps Retatrutide , quintuple agonists, and what's coming out of ADA 2026 If you're on Zepbound , Wegovy , Ozempic , or any GLP-1 medication or you're waiting for the next generation of obesity drugs this episode is for you
Realistic maintenance expectations Finally, if your goal is to maintain, it is important to redefine success as weight maintenance rather than continued loss
(Director of Analytical Sciences, Waters | Wyatt Technology) Sophia received her Ph.D